ITCI Dec 2024 60.000 call
| Previous close | 17.93 |
| Open | 17.93 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 60.00 |
| Expiry date | 2024-12-20 |
| Day's range | 17.93 - 17.93 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireIntra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET in New York, NY. The live and archived webcast can be accessed under "Events &
Insider MonkeyHedge Funds Like Intra-Cellular Therapies (NASDAQ:ITCI)
We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we discuss why hedge funds like Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Challenges in the Health Sector The healthcare industry is considered to be a fairly defensive sector due to its need. According to a World Health Organization […]
- GlobeNewswire
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today highlights data presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held in Miami, May 28 - 31, 2024. The analyses being presented provide important information about CAPLYTA’s efficacy, safety and tolerability profile in
